Biocon’s biologics business has been hit unexpectedly hard due to the pandemic and if the business does not meet our desired growth trajectory, we may defer its IPO (initial public offering) by a few quarters, the company’s executive chairperson Kiran Mazumdar-Shaw said., Biocon’s biologics business has been hit unexpectedly hard due to the pandemic and if the business does not meet our desired growth trajectory, we may defer its IPO (initial public offering) by a few quarters, the company’s executive chairperson Kiran Mazumdar-Shaw said., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way